Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study

[1]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[2]  L. Wallentin,et al.  Early statin treatment following acute myocardial infarction and 1-year survival. , 2001, JAMA.

[3]  F. Mach,et al.  Statins as a newly recognized type of immunomodulator , 2000, Nature Medicine.

[4]  J. W. Schaeffer,et al.  ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) , 2000 .

[5]  J. Concato,et al.  Randomized, controlled trials, observational studies, and the hierarchy of research designs. , 2000, The New England journal of medicine.

[6]  A. Hartz,et al.  A comparison of observational studies and randomized, controlled trials , 2000, American journal of ophthalmology.

[7]  E W Steyerberg,et al.  Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. , 2000, Circulation.

[8]  L. Prosser,et al.  Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics , 2000, Annals of Internal Medicine.

[9]  D. Siegel,et al.  Use of cholesterol-lowering medications in the United States from 1991 to 1997. , 2000, The American journal of medicine.

[10]  H. Krumholz,et al.  Early -Blocker Therapy for Acute Myocardial Infarction in Elderly Patients , 1999, Annals of Internal Medicine.

[11]  E J Topol,et al.  Cause of death in clinical research: time for a reassessment? , 1999, Journal of the American College of Cardiology.

[12]  J S Alpert,et al.  1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) , 1999, Circulation.

[13]  P. Rosenbaum,et al.  Invited commentary: propensity scores. , 1999, American journal of epidemiology.

[14]  R. Knopp.  Drug treatment of lipid disorders. , 1999, The New England journal of medicine.

[15]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[16]  J. Tardif,et al.  Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. , 1999, Circulation.

[17]  Hiroyuki Tanaka,et al.  A986S polymorphism of calcium-sensing receptor , 1999, The Lancet.

[18]  U. Ikeda,et al.  Statins and C-reactive protein , 1999, The Lancet.

[19]  T. Strandberg,et al.  Effect of statins on C-reactive protein in patients with coronary artery disease , 1999, The Lancet.

[20]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[21]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[22]  U. Laufs,et al.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.

[23]  M. Ezekowitz,et al.  Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. , 1998, The American journal of cardiology.

[24]  W. Erl,et al.  HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. , 1997, Journal of the American College of Cardiology.

[25]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[26]  R. Harrington,et al.  Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. , 1997, The American journal of cardiology.

[27]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[28]  M. Simoons.  A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. , 1996, The New England journal of medicine.

[29]  D. Waters,et al.  Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. , 1995, Circulation.

[30]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[31]  T. Rabelink,et al.  Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication , 1995, The Lancet.

[32]  J Col,et al.  Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. , 1995, Circulation.

[33]  G. Davı̀,et al.  Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. , 1995, Arteriosclerosis, thrombosis, and vascular biology.